Kyverna Therapeutics files for IPO as autoimmune CAR-T space heats up

Kyverna Therapeutics, a clinical-stage biotech examining CAR-T cell therapy’s potential to treat autoimmune diseases, has filed for an initial public offering.

The California biotech plans to list as “KYTX” on the Nasdaq, per SEC paperwork filed Tuesday. Endpoints News reported Friday that Kyverna…
Click here to view original post